Aptima® Herpes Simplex 1&2 assay

Identify a Common Viral Threat

Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.1 It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.2, 3
 

The Accurate Testing Needed For Proper Treatment

NAATs, such as the Aptima® HSV 1 & 2 assay, are recommended by the CDC and WHO for HSV diagnosis. They are increasingly preferred over viral culture to diagnose genital herpes due to higher sensitivity, ease of specimen collection and transportation and faster results.2,3 The Aptima HSV 1 & 2 assay distinguishes between HSV-1 and HSV-2 with significant reduction in hands-on time for laboratory professionals when compared to culture and other instrument platforms.4-6


References 1. WHO. Herpes simplex virus. World Health Organization. Last reviewed May 1, 2020. Accessed. September 10, 2021. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus. 2. WHO. WHO guidelines For The Treatment of Genital Herpes Simplex Virus. World Health Organization. Last reviewed March 11, 2016. Accessed September 10, 2021. https://www.who.int/publications/i/item/978924154987 3. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70. 4. Aptima HSV 1 & 2 assay. US package insert AW-15346-001. Hologic, Inc., 2019. 5. LeGoff J, et al. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J. 2014;11:83. doi:10.1186/1743-422X-11-83. 6. A. Jassem, Comparative Evaluation of the Aptima HSV 1&2 Assay and a Lab Developed Real-time PCR Test for Detection of HSV-1 and HSV-2 Viruses, presented at ESCV 2016 Poster No. PP20. 


 

Information provided on this tab is intended for audiences outside the United States. Consult "USA" tab for products and claims available in the United States
 

Identify a Common Viral Threat

Globally, over 4.1 billion people are infected with HSV-1 and HSV-2 and the signs and symptoms can overlap.1 It is only through laboratory tests that these subtypes can be differentiated, which is important for managing herpes infections and identifying the risk of transmission to neonates and among sex partners.2, 3
 

The Accurate Testing Needed For Proper Treatment

NAATs, such as the CE-marked Aptima HSV 1 & 2 assay, are increasingly preferred over viral culture to diagnose genital herpes due to higher sensitivity, ease of specimen collection and transportation and faster results.2,3 The Aptima HSV 1 & 2 assay distinguishes between HSV-1 and HSV-2 with significant reduction in hands-on time for laboratory professionals when compared to culture and other instrument platforms.4-6


References 1. WHO. Herpes simplex virus. World Health Organization. Last reviewed May 1, 2020. Accessed. September 10, 2021. https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus. 2. WHO. WHO guidelines For The Treatment of Genital Herpes Simplex Virus. World Health Organization. Last reviewed March 11, 2016. Accessed September 10, 2021. https://www.who.int/publications/i/item/978924154987 3. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR Recomm Rep 2021;70. 4. Aptima HSV 1 & 2 assay. US package insert AW-15346-001. Hologic, Inc., 2019. 5. LeGoff J, et al. Diagnosis of genital herpes simplex virus infection in the clinical laboratory. Virol J. 2014;11:83. doi:10.1186/1743-422X-11-83. 6. A. Jassem, Comparative Evaluation of the Aptima HSV 1&2 Assay and a Lab Developed Real-time PCR Test for Detection of HSV-1 and HSV-2 Viruses, presented at ESCV 2016 Poster No. PP20. 


 


 

Want Image Slider on Tab Click
no